Description
Prevention of new intramammary infections throughout the dry period. In cows considered likely to be free of sub-clinical mastitis, the product may be suitable for use on its own in dry cow management for mastitis control.
Selection of cows for treatment with the product should be based on veterinary clinical judgement.
Selection criteria may be based on the mastitis and cell count history of individual cows, or recognised tests for the detection of sub-clinical mastitis or bacteriological sampling.
resentation
Tubs of 120 4g applicator syringes containing 650 mg/g Bismuth subnitrate
Uses
For the prevention of mastitis in dairy cows during the non-lactating (dry) period and early post-calving.
Dosage & Administration
READ THE ENCLOSED DOSAGE AND ADMINISTRATION LEAFLET BEFORE USING THIS PRODUCT
During the administration of the product it is important to ensure that infection is not introduced. Accidental introduction of bacteria into the quarter during insertion of the intramammary syringe can result in serious mastitis. Thoroughly clean hands prior to administration and wear clean gloves during administration. Immediately after the last milking at drying off, prior to treatment with Sureseal, the udder should be stripped and each teat thoroughly cleaned with a suitable disinfectant.
Carefully infuse the entire contents of one injector into each teat to form a seal, preventing the ingress of pathogenic bacteria into the udder during the dry period.
After infusion DO NOT massage or squeeze the teat as this may dislodge the seal.
It is recommended that Sureseal be used as part of a herd approach to dry cow management and mastitis control. Cows considered likely to be free of subclinical mastitis and at risk for new infection in the dry period should be given Sureseal at drying off. Other animals should be managed in accordance with an approved mastitis control plan or specific veterinary advice.
For practical purposes, selection criteria may be based on the mastitis and cell count history of individual cows, or recognised tests for the detection of subclinical mastitis, or bacteriological sampling. As a guide, where there has been no episode of clinical mastitis and at least three individual cow cell counts are available, cows with all cell counts below 250,000 cells/mL may be given Sureseal.
Maiden heifers (first calvers): Administer Sureseal approximately 4 weeks prior to calving to reduce the risk of post-calving mastitis.
Use in combination with antibiotic therapy: In cows that have sub-clinical mastitis, Sureseal may be used following administration of a suitable dry cow antibiotic treatment to the infected quarter. The dry cow antibiotic should be administered in accordance with the product label and massaged into the quarter. Following administration redisinfect the teat and infuse Sureseal as recommended above. After Sureseal infusion DO NOT massage or squeeze the teat as this may dislodge the seal.
Withdrawal Period
MILK: DO NOT USE in lactating cows or within 4 days of calving. After calving, colostrum or milk from treated dry cows MUST NOT BE USED for human consumption or processing for 96 hours (8 milkings).
MEAT: Zero (0) days.
